Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Trifluoperazine hydrochloride
Drug ID BADD_D02282
Description A phenothiazine with actions similar to chlorpromazine. It is used as an antipsychotic and an antiemetic.
Indications and Usage For the treatment of anxiety disorders, depressive symptoms secondary to anxiety and agitation.
Marketing Status Prescription; Discontinued
ATC Code N05AB06
DrugBank ID DB00831
KEGG ID D00799
MeSH ID D014268
PubChem ID 66064
TTD Drug ID D0R4OM
NDC Product Code 0378-2405; 51079-575; 51079-573; 51079-572; 0832-0495; 0378-2401; 0832-0496; 0781-8028; 0378-2402; 0832-0494; 0781-8034; 0378-2410; 46204-0081; 51079-574; 0781-8036; 70518-2106; 70518-2095; 0832-0497; 0781-8032
Synonyms Trifluoperazine | Trifluperazine | Trifluoroperazine | Eskazine | Flupazine | Terfluzine | Trifluoperazine Hydrochloride | Trifluoperazine HCL | Triftazin | Apo-Trifluoperazine | Apo Trifluoperazine | ApoTrifluoperazine | Stelazine
Chemical Information
Molecular Formula C21H26Cl2F3N3S
CAS Registry Number 440-17-5
SMILES CN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F.Cl.Cl
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Tardive dyskinesiaD(4) dopamine receptorP21917T24983Not Available
Tardive dyskinesiaD(2) dopamine receptorP14416T67162Not Available
Tardive dyskinesiaD(3) dopamine receptorP35462T02551Not Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Mydriasis17.02.11.003; 06.05.03.004--Not Available
Nasal congestion22.04.04.001--
Nausea07.01.07.001--
Neuroleptic malignant syndrome17.05.02.003; 15.05.04.015; 12.03.01.003; 08.05.01.005--Not Available
Oculogyric crisis17.01.03.002; 06.05.02.002--Not Available
Oedema peripheral08.01.07.007; 02.05.04.007; 14.05.06.011--
Opisthotonus17.01.03.005--Not Available
Pancytopenia01.03.03.003--Not Available
Parkinsonism17.01.05.003--Not Available
Photosensitivity reaction23.03.09.003--
Pregnancy test false positive13.10.05.003--Not Available
Priapism21.03.01.005--Not Available
Protrusion tongue07.14.02.002; 17.02.05.037--Not Available
Pruritus23.03.12.001--
Rash23.03.13.001--Not Available
Retinal dystrophy06.09.03.012--Not Available
Seizure17.12.03.001--
Skin disorder23.03.03.007--Not Available
Skin reaction23.03.03.013; 10.01.03.019--Not Available
Somnolence19.02.05.003; 17.02.04.006--
Swelling face23.04.01.018; 10.01.05.018--Not Available
Systemic lupus erythematosus23.03.02.006; 15.06.02.003; 10.04.03.004--Not Available
Tardive dyskinesia17.01.02.012--Not Available
Throat tightness19.01.02.005; 22.02.05.015--Not Available
Thrombocytopenic purpura23.06.01.007; 01.08.01.003--Not Available
Tremor17.01.06.002--
Urticaria23.04.02.001; 10.01.06.001--
Vision blurred17.17.01.010; 06.02.06.007--
Vomiting07.01.07.003--
Weight increased13.15.01.006--
The 3th Page    First    Pre   3 4    Next   Last    Total 4 Pages